Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Vitalik publishes GKR tutorial article: The "Batch × Layer" protocol powering ultra-fast ZK proofs

Vitalik publishes GKR tutorial article: The "Batch × Layer" protocol powering ultra-fast ZK proofs

ChaincatcherChaincatcher2025/10/20 00:23
Show original

ChainCatcher reported that Vitalik Buterin has published a new article detailing how the GKR (Goldreich–Kahan–Rothblum) protocol is used to accelerate ZK proofs, adapting to a "batch × multi-layer" computational structure, significantly reducing intermediate layer commitments and committing only to inputs and outputs.

The article uses Poseidon2 hash as an example to explain in detail the recursive proof process centered on sumcheck, and provides optimizations (Gruen’s trick, linear batching, and only cubing the first element in some rounds). In polynomial commitment scenarios, it can be combined with BaseFold or FRI. The author states that the actual overhead is about 100 times lower than the theoretical value of traditional STARK, making single-digit level overhead achievable, and reminds that Fiat–Shamir challenges need to guard against predictability risks within the circuit.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.

U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).

智通财经2026/09/21 07:11

Pfizer (PFE.US) overseas price increase gains to be shared with the U.S. government: "Most Favored Nation" contract revealed, over twenty transactions still confidential

According to reports, under a new contract with the U.S. Department of Health and Human Services, Pfizer will share higher overseas drug revenues with the United States.

智通财经2026/09/21 07:11

Autoimmune and inflammatory disease pharmaceutical company TRex Bio (TRX.US) applies for US listing, plans to raise up to 100 millions dollars.

TRex Bio filed documents with the U.S. Securities and Exchange Commission (SEC) last Friday, intending to raise up to 100 million USD through an initial public offering (IPO).

智通财经2026/09/21 07:11